“Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics, and prophylactics to fight against COVID-19,” said Philippe Funfrock, co-founder and president of ProteoGenix. “The new Human Immune COVID-19 antibody library developed by ProteoGenix represents an exciting opportunity to solve the current pandemic.”
Get the full story on our WTWH Media sister site R&D World.
Filed Under: Drug Discovery and Development, Infectious Disease
Tell Us What You Think!
You must be logged in to post a comment.